Open Access
Ann Toxicol Anal
Volume 23, Numéro 3, 2011
Page(s) 147 - 153
Publié en ligne 17 octobre 2011
  1. Mele TS,Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 2000; 47(2-3) : 215–245. [CrossRef] [PubMed]
  2. Westley IS,Sallustio BC,Morris RG. Validation of high-performance liquid chromatography method for the measurement of mycophenolic acid and its glucuronide metabolites in plasma. Clin Biochem. 2005; 38(9) : 824–829. [CrossRef] [PubMed]
  3. Irtan S,Azougagh S,Monchaud C,Popon M,Baudouin V,Jacqz-Aigrain E. Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatr Nephrol. 2008; 23(10) : 1859–1865. [CrossRef] [PubMed]
  4. Hosotsubo H,Takahara S,Imamura R,Kyakuno M,Tanaka T,Yazawa K,Hanafusa T,Matsumiya K,Nonomura N,Okuyama A,Sugimoto H. Analytic validation of the enzyme multiplied immunoassay technique for the determination of mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatographic assay. Ther Drug Monit. 2001; 23(6) : 669–674. [CrossRef] [PubMed]
  5. Van Hest RM,Van Gelder T,Vulto AG,Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2005; 44(10) : 1083–1096. [CrossRef] [PubMed]
  6. Pelletier RP,Akin B,Henry ML,Bumgardner GL,Elkhammas EA,Rajab A,Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 2003; 17(3) : 200–205. [CrossRef] [PubMed]
  7. Borrows R,Chusney G,James A,Stichbury J,Van Tromp J,Cairns T,Griffith M,Hakim N,McLean A,Palmer A,Papalois V,Taube D. Determinants of mycophenolic acid levels after renal transplantation. Ther Drug Monit. 2005; 27(4) : 442–450. [CrossRef] [PubMed]
  8. Staatz CE,Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007; 46(1) : 13–58. [CrossRef] [PubMed]
  9. Cox VC,Ensom MH. Mycophenolate mofetil for solid organ transplantation : does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003; 25(2) : 137–157. [CrossRef] [PubMed]
  10. Prémaud A, Le Meur Y,Debord J,Szelag JC,Rousseau A,Hoizey G,Toupance O,Marquet P. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005; 27(3) : 354–361. [CrossRef] [PubMed]
  11. Van Gelder T,Silva HT, de Fijter H,Budde K,Kuypers D,Mamelok RD,Armstrong VW,Oellerich M. How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation. Ther Drug Monit. 2011; 33(2) : 155–164. [PubMed]
  12. Prémaud A,Rousseau A,Picard N,Marquet P. Determination of mycophenolic acid plasma levels in renal transplant recipients co-administered sirolimus : comparison of an enzyme multiplied immunoassay technique (EMIT) and liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2006; 28(2) : 274–277. [CrossRef] [PubMed]
  13. Shipkova M,Schütz E,Besenthal I,Fraunberger P,Wieland E. Investigation of the crossreactivity of mycophenolic acid glucuronid metabolites and of Mycophenolate mofetil in the Cedia MPA assay. Ther Drug Monit. 2010; 32(1) : 79–85. [CrossRef] [PubMed]
  14. Westley IS,Taylor PJ,Salm P,Morris RG. Cloned enzyme donor immunoassay tacrolimus assay compared with high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in liver and renal transplant recipients. Ther Drug Monit. 2007; 29(5) : 584–591. [CrossRef] [PubMed]
  15. Marquet P,Saint-Marcoux F,Prémaud A,Sauvage FL,Jaqz-Aigrain E,Knoop C,Lebranchu Y,Tiberi M,Domke I,Debord J. Performance of the new mycophenolate assay based on IMPDH enzymatic activity for pharmacokinetic investigations and setup of Bayesian estimators in different populations of allograft recipients. Ther Drug Monit. 2009; 31(4) : 443–450. [CrossRef] [PubMed]
  16. Blanchet B, Taieb F, Conti F, Abbas H, Seydi I, Harcouet L, Dauphin A, Calmus Y, Tod M Comparison of a new enzymatic assay with a high-performance liquid chromatography/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients. Liver Transpl. 2008; 14(12) : 1745–1751. [CrossRef] [PubMed]
  17. Vogl M,Weigel G,Seebacher G,Griesmacher A,Laufer G,Müller MM. Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring. Ther Drug Monit. 1999; 21(6) : 638–643. [CrossRef] [PubMed]
  18. Beal JL,Jones CE,Taylor PJ,Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit. 1998; 20(6) : 685–690. [CrossRef] [PubMed]
  19. Shipkova M,Schütz E,Armstrong VW,Niedmann PD,Wieland E,Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc. 1999; 31(1-2) : 1135–1137. [CrossRef] [PubMed]
  20. Shen B,Li S,Zhang Y,Yuan X,Fan Y,Liu Z,Hu Q,Yu C. Determination of total, free and saliva mycophenolic acid with a LC-MS/MS method : application to pharmacokinetic study in healthy volunteers and renal transplant patients. J Pharm Biomed Anal. 2009; 50(3) : 515–521. [CrossRef] [PubMed]
  21. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L,Bresnahan B,Darji P,Massari P,Mondragon-Ramirez GA,Agarwal M,Di Russo G,Lin CS,Garg P,Larsen CP. A phase III study of bélatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10 : 535–546. [CrossRef] [PubMed]
  22. Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C,Kamar N,Block A,Di Russo G,Lin CS,Garg P,Charpentier B. Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients : 2-years results from the BENEFIT and BENEFIT-EXT studies. Transplantation. 2010; 90(12) : 1528–1535. [CrossRef] [PubMed]
  23. Latek R, Fleener C, Lamian V, Kulbokas E 3rd, Davis PM,Suchard SJ,Curran M,Vincenti F,Townsend R. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation. 2009; 87(6) : 926–933. [CrossRef] [PubMed]
  24. Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L. Biological agents in kidney transplantation : bélatacept is entering the field. Expert Opin Biol Ther. 2010; 10 (10) : 1501–1508.
  25. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C,Florman S,Block A,Di Russo G,Xing J,Garg P,Grinyó J. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10 : 547–557. [CrossRef] [PubMed]
  26. Guidance for industry. Bioanalytical method validation. U.S. Department of health and human services/Food and drug administration/Center for drug evaluation and research (CDER)/Center for veterinary medicine (CVM). May 2001. Document consulté sur le site le 18/04/2011.
  27. Hosotsubo H,Takahara S,Kokado Y,Permpongkosol S,Wang JD,Tanaka T,Matsumiya K,Kitamura M,Okuyama A,Sugimoto H. Rapid and simultaneous determination of mycophenolic acid and its glucuronide conjugate in human plasma by ion-pair reversed-phase high-performance liquid chromatography using isocratic elution. J chromatogr B Biomed Sci Appl. 2001; 753(2) : 315–320. [CrossRef] [PubMed]
  28. Bland JM,Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986; 1 : 307–310. [CrossRef] [PubMed]
  29. Passing H,Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in Clinical Chemistry. Part I. J Clin Chem Clin Biochem. 1983; 21 : 709–720.
  30. Manuel du logiciel statEL® Statistical software. Document consulté sur le site le 18/04/2011
  31. Journois D. Concordance between two variables : graphical approach (Bland and Altman’s method). Rev Mal Resp. 2004; 21 : 127–130.
  32. Manuel du logiciel MedCalc®. Document consulté sur le site le 18/04/2011.
  33. Bullingham RE,Nicholls AJ,Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998; 34(6) : 429–455. [CrossRef] [PubMed]
  34. Sam WJ,Akhlaghi F,Rosenbaum SE. Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. J Clin Pharmacol. 2009; 49(2) : 185–195. [CrossRef] [PubMed]
  35. Kuhn J,Prante C,Kleesiek K,Götting C. Measurement of mycophenolic acid and its glucuronide using a novel rapid liquid chromatography-electrospray ionization tandem mass spectrometry assay. Clin Biochem. 2009; 42(1-2) : 83–90. [CrossRef] [PubMed]
  36. Naesens M, de Loor H,Vanrenterghem Y,Kuypers DR. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. Transplantation. 2007; 84(3) : 362–373. [CrossRef] [PubMed]
  37. Schütz E,Shipkova M,Armstrong VW,Niedmann PD,Weber L,Tönshoff B,Pethig K,Wahlers T,Braun F,Ringe B,Oellerich M. Therapeutic drug monitoring of mycophenolic acid : comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc. 1998; 30 : 1185–1187. [CrossRef] [PubMed]